Versant Ventures joined the ranks of venture capital firms closing new funds recently, thanks in part to the swell in biotech initial public offerings this year. In the case of Versant’s Fund V, however, the firm has built in at least part of an exit strategy as a defining feature of the fund. The firm announced on December 10th
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?